The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
-
Comprehensive Blood and Cancer Center, Bakersfield, California, United States, 93309
City of Hope National Medical Center, Duarte, California, United States, 91010
Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California, United States, 90095
University of California Los Angeles, Santa Monica, California, United States, 90404
Rocky Mountain Cancer Centers, Aurora, Colorado, United States, 80012
Hartford Hospital, Hartford, Connecticut, United States, 06106
Norwalk Hospital, Norwalk, Connecticut, United States, 06856
Indiana University, Indianapolis, Indiana, United States, 46202
Norton Cancer Institute, Louisville, Kentucky, United States, 40202
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 100 Years
ALL
No
Amgen,
MD, STUDY_DIRECTOR, Amgen
2028-04-30